Schering Foradil Detail Aid Implies Overly Broad Asthma Claim, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Marketing material also "fails to reveal important risk information" about the bronchodilator, the ad division letter states. Schering says the aid was used for a specific managed care audience and was discontinued earlier in the year.